These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 1643641)

  • 1. Benzopyranones and benzothiopyranones: a class of tyrosine protein kinase inhibitors with selectivity for the v-abl kinase.
    Geissler JF; Roesel JL; Meyer T; Trinks UP; Traxler P; Lydon NB
    Cancer Res; 1992 Aug; 52(16):4492-8. PubMed ID: 1643641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
    Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.
    Buchdunger E; Zimmermann J; Mett H; Meyer T; Müller M; Druker BJ; Lydon NB
    Cancer Res; 1996 Jan; 56(1):100-4. PubMed ID: 8548747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.
    Showalter HD; Sercel AD; Leja BM; Wolfangel CD; Ambroso LA; Elliott WL; Fry DW; Kraker AJ; Howard CT; Lu GH; Moore CW; Nelson JM; Roberts BJ; Vincent PW; Denny WA; Thompson AM
    J Med Chem; 1997 Feb; 40(4):413-26. PubMed ID: 9046331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.
    Traxler PM; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Med Chem; 1996 Jun; 39(12):2285-92. PubMed ID: 8691423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction by some protein kinase inhibitors of differentiation of a mouse megakaryoblastic cell line established by coinfection with Abelson murine leukemia virus and recombinant SV40 retrovirus.
    Honma Y; Okabe-Kado J; Kasukabe T; Hozumi M; Kajigaya S; Suda T; Miura Y
    Cancer Res; 1991 Sep; 51(17):4649-55. PubMed ID: 1651810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation of a phenylalanine conserved in SH3-containing tyrosine kinases activates the transforming ability of c-Abl.
    Jackson PK; Paskind M; Baltimore D
    Oncogene; 1993 Jul; 8(7):1943-56. PubMed ID: 8510937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of a series of flavones designed as inhibitors of protein tyrosine kinases.
    Cunningham BD; Threadgill MD; Groundwater PW; Dale IL; Hickman JA
    Anticancer Drug Des; 1992 Oct; 7(5):365-84. PubMed ID: 1388629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor.
    Panek RL; Lu GH; Klutchko SR; Batley BL; Dahring TK; Hamby JM; Hallak H; Doherty AM; Keiser JA
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1433-44. PubMed ID: 9400019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.
    Traxler P; Bold G; Frei J; Lang M; Lydon N; Mett H; Buchdunger E; Meyer T; Mueller M; Furet P
    J Med Chem; 1997 Oct; 40(22):3601-16. PubMed ID: 9357527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients.
    Maxwell SA; Kurzrock R; Parsons SJ; Talpaz M; Gallick GE; Kloetzer WS; Arlinghaus RB; Kouttab NM; Keating MJ; Gutterman JU
    Cancer Res; 1987 Mar; 47(6):1731-9. PubMed ID: 2434223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD 089828, a new synthetic protein tyrosine kinase inhibitor.
    Dahring TK; Lu GH; Hamby JM; Batley BL; Kraker AJ; Panek RL
    J Pharmacol Exp Ther; 1997 Jun; 281(3):1446-56. PubMed ID: 9190882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. bcr/abl expression in 32D cl3(G) cells inhibits apoptosis induced by protein tyrosine kinase inhibitors.
    Laneuville P; Timm M; Hudson AT
    Cancer Res; 1994 Mar; 54(5):1360-6. PubMed ID: 8118826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drosophila abelson interacting protein (dAbi) is a positive regulator of abelson tyrosine kinase activity.
    Juang JL; Hoffmann FM
    Oncogene; 1999 Sep; 18(37):5138-47. PubMed ID: 10498863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells.
    Evans CA; Owen-Lynch PJ; Whetton AD; Dive C
    Cancer Res; 1993 Apr; 53(8):1735-8. PubMed ID: 8467488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
    Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
    J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
    Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
    J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of cell growth: effects of the tyrosine kinase inhibitor CGP 53716.
    Major TC; Keiser JA
    J Pharmacol Exp Ther; 1997 Oct; 283(1):402-10. PubMed ID: 9336349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.
    Matulonis U; Salgia R; Okuda K; Druker B; Griffin JD
    Exp Hematol; 1993 Oct; 21(11):1460-6. PubMed ID: 8405226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.
    Buchdunger E; Cioffi CL; Law N; Stover D; Ohno-Jones S; Druker BJ; Lydon NB
    J Pharmacol Exp Ther; 2000 Oct; 295(1):139-45. PubMed ID: 10991971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.